FDA Clearance Tracker · P160045-S035
Oncomine Dx Target Test
Last checked: Nov 20, 2026Latest source record: Aug 11, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Aug 11, 2022
Approved
Time to decision
156 days
Received Mar 8, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160045-S035
- Device name
- Oncomine Dx Target Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Carlsbad, CA
- Received
- Mar 8, 2022
- Decided
- Aug 11, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160045
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the indications for use to include a companion diagnostic indication for the detection of ERBB2 activating mutations (SNVs and exon 20 insertions) in non-small cell lung cancer patients who may benefit from treatment with ENHERTU® (fam-trastuzumab deruxtecan-nxki).
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P240040 · Decided Jul 2, 2025 · 232 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.